Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current (N=451) MDD or without psychiatric disorders (N=4,028).

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

The timeline in the abstract includes 12 weeks.

The primary safety outcome was occurrence of one or more moderate to severe neuropsychiatric adverse events.

What Was Measured

PubMed files the paper under topics including Varenicline, Bupropion, Major Depressive Disorder, Smoking Cessation, Tobacco Use Cessation Devices, Smoking Cessation Agents and Smoking.

Author keywords: Drug/Psychotherapy Combination, Nicotine and Substance-Related and Addictive Disorders.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) over 12 weeks.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (The American journal of psychiatry), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.